TCT to Katie Weimer, MS, MBA, CEO and Co-founder at GenesisTissue Inc. about launching a new 3D bioprinting company that goes ‘beyond repair to true regeneration.’
TCT: You just announced your new company GenesisTissue Inc. - congratulations! Tell us about your ambition.
KW: GenesisTissue Inc. (GTI) is set to revolutionize surgery by designing and manufacturing personalized regenerative implants, starting with adipose tissue. The company’s ambition is to transform how soft tissue defects are reconstructed by providing bioresorbable, patient-specific implants that promote true adipose tissue regeneration. GenesisTissue is leveraging cutting-edge 3D bioprinting technology to create implants that seamlessly integrate with the body, reducing complications, and eliminating the need for secondary operations.
TCT: Stepping out with this new venture, what are you aiming to do differently in the 3D bioprinting space?
KW: GenesisTissue’s core mission centers on two key technological advances – personalization and tissue engineering. Of course, there is a long history in the industry of personalized medical devices such as anatomic models, cutting guides and titanium implants. Additionally, there are several groups focused on 3D bioprinting tissues and organs. GenesisTissue is uniquely positioned to do both. By combining surgical planning, patient specific design, and bioprinting, we are ensuring that each regenerative implant matches the patient’s anatomy and clinical needs.
